| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On November 12, 2026, Elicio Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company considered and voted on two proposals, each of wh... |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Elicio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • AMPLIFY-7P Phase 2 pre-specified analyses demonstrate substantial reductions in risk of recurrence or death in ctDNA negative patients and pa... |
| 09 Oct 2026 | Proxy statement: annual meeting on November 12, 2026 |
| 14 Sep 2026 |
8-K: Shareholder Director Nominations; Other Events
To the extent applicable, the information set forth below under Item 8.01 of this Current Report on Form 8-K “Notice of Annual Meeting” is incorporated by reference into this Item 5.08. |
| 02 Sep 2026 |
Form 4: Adams Julian, Director
Granted 21,750 Stock Option (Right to Buy) |
| 02 Sep 2026 |
Form 4: Ashe Carol Gail, Director
Granted 21,750 Stock Option (Right to Buy) |
| 02 Sep 2026 |
Form 4: Chudnovsky Yekaterina, Director
Granted 21,750 Stock Option (Right to Buy) |
| 02 Sep 2026 |
Form 4: Nissenson Allen, Director
Granted 21,750 Stock Option (Right to Buy) |
| 02 Sep 2026 |
Form 4: Ruffolo Robert R, Director
Granted 21,750 Stock Option (Right to Buy) |
| 02 Sep 2026 |
Form 4: Wilson Karen J, Director
Granted 21,750 Stock Option (Right to Buy) |
| 02 Sep 2026 |
Form 4: Venkatesan Jay, Director
Granted 21,750 Stock Option (Right to Buy) |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS sm... |
| 17 Jul 2026 |
Form 4: Haqq Christopher, See Remarks
Granted 64,643 Stock Option (Right to Buy) |
| 17 Jul 2026 |
Form 4: DeMuth Peter, Chief Scientific Officer
Granted 52,832 Stock Option (Right to Buy) |
| 17 Jul 2026 |
Form 4: Shah Preetam, See Remarks
Granted 60,833 Stock Option (Right to Buy) |
| 17 Jul 2026 |
Form 4: Connelly Robert, Director
Granted 186,944 Stock Option (Right to Buy) |
| 16 Jul 2026 | SCHEDULE 13G |
| 08 Jul 2026 | SCHEDULE 13G/A |
Loading...